Trial Profile

A phase 1 clinical trial to determine the maximum tolerated dose (MTD) for three different cycles of AB8939.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AB-8939 (Primary) ; Azacitidine (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use

Most Recent Events

17 Oct 2025 Results presented in an AB Science media release.
14 Oct 2025 trial event According to AB SCIENCE media release, the company will host a virtual conference on Thursday, October 16, 2025 ,to provide an update on the Phase 1 study with AB8939
14 Oct 2025 According to AB SCIENCE media release, this trial has completed first two stages determining the maximum tolerated dose after 3 and 14 consecutive days of monotherapy.The third stage is currently underway evaluating the combination of AB8939 + Venetoclax.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com